
## Julio Cb Moraes

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5155990/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Abatacept induced long-term non-progressive reduction in gamma-globulins and autoantibodies: dissociation from disease activity control. Clinical Rheumatology, 2020, 39, 1747-1755.	2.2	3
2	Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area. Clinics, 2020, 75, e1870.	1.5	4
3	NT-proBNP levels may be influenced by inflammation in active ankylosing spondylitis receiving TNF blockers: a pilot study. Clinical Rheumatology, 2013, 32, 879-883.	2.2	15
4	Testicular Sertoli cell function in ankylosing spondylitis. Clinical Rheumatology, 2013, 32, 1075-1079.	2.2	24
5	Pandemic influenza vaccine in granulomatosis with polyangiitis: Adequate humoral response and safety in inactive patients. Presse Medicale, 2013, 42, 706.	1.9	0
6	Immunogenicity and safety of two doses of a non-adjuvanted influenza A H1N1/2009 vaccine in young autoimmune rheumatic diseases patients. Lupus, 2013, 22, 1394-1398.	1.6	17
7	High Disease Activity: An Independent Factor for Reduced Immunogenicity of the Pandemic Influenza A Vaccine in Patients With Juvenile Systemic Lupus Erythematosus. Arthritis Care and Research, 2013, 65, 1121-1127.	3.4	59
8	Abatacept and reduced immune response to pandemic 2009 influenza A/H1N1 vaccination in patients with rheumatoid arthritis. Arthritis Care and Research, 2013, 65, 476-480.	3.4	95
9	Immunogenicity of influenza H1N1 vaccination in mixed connective tissue disease: effect of disease and therapy. Clinics, 2013, 68, 129-133.	1.5	14
10	TNF blockers show distinct patterns of immune response to the pandemic influenza A H1N1 vaccine in inflammatory arthritis patients. Rheumatology, 2012, 51, 2091-2098.	1.9	56
11	Influenza A/H1N1 vaccination of patients with SLE: can antimalarial drugs restore diminished response under immunosuppressive therapy?. Rheumatology, 2012, 51, 1061-1069.	1.9	57
12	Low sclerostin levels: a predictive marker of persistent inflammation in ankylosing spondylitis during anti-tumor necrosis factor therapy?. Arthritis Research and Therapy, 2012, 14, R216.	3.5	58
13	Intestinal microsporidiosis: a hidden risk in rheumatic disease patients undergoing anti-tumor necrosis factor therapy combined with disease-modifying anti-rheumatic drugs?. Clinics, 2011, 66, 1171-1175.	1.5	14
14	Immunogenicity and safety of the 2009 non-adjuvanted influenza A/H1N1 vaccine in a large cohort of autoimmune rheumatic diseases. Annals of the Rheumatic Diseases, 2011, 70, 1068-1073.	0.9	87
15	Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients. Clinical and Developmental Immunology, 2011, 2011, 1-5.	3.3	25
16	Reduced seroprotection after pandemic H1N1 influenza adjuvant-free vaccination in patients with rheumatoid arthritis: implications for clinical practice. Annals of the Rheumatic Diseases, 2011, 70, 2144-2147.	0.9	76
17	Cross-cultural adaptation of the Behçet's Disease Current Activity Form (BDCAF) to Brazilian Portuguese language. Clinical Rheumatology, 2007, 26, 1263-1267.	2.2	37